Literature DB >> 28825192

Teniposide ameliorates bone cancer nociception in rats via the P2X7 receptor.

Jingjia Yan1, Jiaxiao Sun1, Zhiyuan Zeng2.   

Abstract

Bone pain associated with advanced tumor metastasis is the most severe threat to life quality of patients. Highly efficient and low-toxic therapeutics is of urgent need for this complication. Bone tumor metastasis was established by direct bone inoculation of Walker 256 mammary gland carcinoma cells. Bone nociception was measured by mechanical allodynia, thermal hyperalgesia and spontaneous flinches. P2X7R level was determined by immunoblotting. The inward current was recorded by a patch clamp. The related cytokines were determined by ELISA. Our results showed that teniposide (TN) treatment significantly ameliorated bone nociception associated with tumor inoculation to a comparable extent with P2X7-specific inhibitor, BBG, in rat model. The efficient blockade of inward current generation and pro-inflammatory cytokines secretion were observed upon administration with TN. Our data highlighted the therapeutic potency of TN in this complication associated with tumor metastasis and warrants further clinical investigations.

Entities:  

Keywords:  ATP; Bone nociception; Inflammation; P2X7R; Teniposide

Mesh:

Substances:

Year:  2017        PMID: 28825192     DOI: 10.1007/s10787-017-0388-2

Source DB:  PubMed          Journal:  Inflammopharmacology        ISSN: 0925-4692            Impact factor:   4.473


  32 in total

Review 1.  Strategies in pain management: new and potential indications for COX-2 specific inhibitors.

Authors:  Gary Ruoff; Mark Lema
Journal:  J Pain Symptom Manage       Date:  2003-02       Impact factor: 3.612

2.  Cancer: an inflammatory link.

Authors:  Fran Balkwill; Lisa M Coussens
Journal:  Nature       Date:  2004-09-23       Impact factor: 49.962

Review 3.  Emerging therapies in bone metastasis.

Authors:  Lise Clément-Demange; Philippe Clézardin
Journal:  Curr Opin Pharmacol       Date:  2015-05-14       Impact factor: 5.547

Review 4.  Neurotrophins and hyperalgesia.

Authors:  X Q Shu; L M Mendell
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

5.  Expression of P2X7 receptor increases in vivo tumor growth.

Authors:  Elena Adinolfi; Lizzia Raffaghello; Anna Lisa Giuliani; Luigi Cavazzini; Marina Capece; Paola Chiozzi; Giovanna Bianchi; Guido Kroemer; Vito Pistoia; Francesco Di Virgilio
Journal:  Cancer Res       Date:  2012-04-13       Impact factor: 12.701

Review 6.  Immune cell regulation by autocrine purinergic signalling.

Authors:  Wolfgang G Junger
Journal:  Nat Rev Immunol       Date:  2011-02-18       Impact factor: 53.106

Review 7.  Cancer-related pain management: A review of knowledge and attitudes of healthcare professionals.

Authors:  M A M Kasasbeh; C McCabe; S Payne
Journal:  Eur J Cancer Care (Engl)       Date:  2016-12-27       Impact factor: 2.520

Review 8.  Inflammation: gearing the journey to cancer.

Authors:  Joydeb Kumar Kundu; Young-Joon Surh
Journal:  Mutat Res       Date:  2008-03-16       Impact factor: 2.433

Review 9.  Bone cancer pain: causes, consequences, and therapeutic opportunities.

Authors:  Patrick Mantyh
Journal:  Pain       Date:  2013-07-31       Impact factor: 6.961

Review 10.  Nucleotide signalling during inflammation.

Authors:  Marco Idzko; Davide Ferrari; Holger K Eltzschig
Journal:  Nature       Date:  2014-05-15       Impact factor: 49.962

View more
  2 in total

1.  Design and Synthesis of Novel Podophyllotoxins Hybrids and the Effects of Different Functional Groups on Cytotoxicity.

Authors:  Zhongtao Yang; Zitong Zhou; Xiai Luo; Xiaoling Luo; Hui Luo; Lianxiang Luo; Weiguang Yang
Journal:  Molecules       Date:  2021-12-30       Impact factor: 4.411

2.  Systematically integrative analysis identifies diagnostic and prognostic candidates and small-molecule drugs for lung adenocarcinoma.

Authors:  Qiang Chen; Xiaoyi Wang; Jing Hu
Journal:  Transl Cancer Res       Date:  2021-08       Impact factor: 1.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.